Actively Recruiting
Group O Whole Blood (LTO-WB): Storage Lesion Impact and Inflammation
Led by Etablissement Français du Sang · Updated on 2025-08-06
30
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
Sponsors
E
Etablissement Français du Sang
Lead Sponsor
C
Centre de transfusion sanguine des Armées, Clamart, France
Collaborating Sponsor
AI-Summary
What this Trial Is About
Researchers are studying the inflammatory and biological characteristics of blood products prepared by two different organizations: the Etablissement Français du Sang (EFS), which produces standard blood components like red blood cells, plasma, and platelets, and the Centre de Transfusion Sanguine des Armées (CTSA), which produces an innovative group O leukocyte-free whole blood product called LTO-WB. This research is important because hemorrhage is a major cause of preventable death in combat, and current blood component supplies may not always be available or suitable in military operations. The study compares LTO-WB with conventional blood products including platelet concentrates, red blood cell concentrates, and fresh frozen plasma, focusing on inflammation related to platelets and red blood cells. Participants donate either whole blood or plasma/platelet products via apheresis. These donations are analyzed over time to assess inflammatory markers and biological changes during storage. Participants will be involved in blood donation procedures and subsequent laboratory analyses will measure inflammatory potential related to platelets at multiple time points during storage, from Day 2 through Day 42. The study aims to identify biomarkers that can optimize transfusion use in both military and civilian settings. This research is sponsored by Etablissement Français du Sang and includes healthy volunteer blood donors aged 18 to 70 for whole blood and 18 to 65 for apheresis donations.
CONDITIONS
Brief Title
grouP O wholE blooD : storagE leSion impacT And infLammation
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Self-referred donors eligible for blood donation (whole blood and/or plasma/platelet apheresis)
- Be in good health
- Weigh at least 50 kg
- Be between 18 and 70 years old for whole blood donation
- Be between 18 and 65 years old for plasma or platelet donation by apheresis
You will not qualify if you...
- Subjects ineligible to donate blood
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - Single day
Participants donate whole blood or undergo plasma/platelet apheresis donation depending on their assigned group.
1 donation visit (in-person)
Duration - Up to 42 days
Blood products collected from donations are monitored over time to assess platelet-related inflammatory potential throughout storage.
Multiple sample assessments on Days 2, 4, 6, 8, 10, 12, 14, 21, 28, 35, and 42
Trial Site Locations
Total: 1 location
1
Maison du don de l'EFS Auvergne Rhônes-Alpes
Saint-Etienne, France, 42100
Actively Recruiting
Research Team
H
Hind HAMZEH-COGNASSE, PhD, HDR
F
Fabrice COGNASSE, PhD, HDR
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
BASIC_SCIENCE
Number of Arms
2
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here